Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab

Jacqueline A Nicholas,Mark Gudesblatt,Meghan Garabedian,Nicholas Belviso,Changyu Shen,Caroline Geremakis, Sai L Shankar,Jason P Mendoza,James B Lewin

Multiple Sclerosis and Related Disorders（2022）

引用 0|浏览2

暂无评分

摘要

•DMF-treated patients had a lower infection risk than matched OCR-treated patients.•Infection-related healthcare costs were lower for DMF- vs OCR-treated patients.•Inpatient infections accounted for most of the healthcare cost difference.

查看译文

关键词

Multiple sclerosis,Dimethyl fumarate,Ocrelizumab,Infection,Healthcare resource utilization,Healthcare resource costs

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要